menu
    • menu
    [{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterin Announces FDA Acceptance of An Investigator Sponsored IND To Treat a Patient with Prodromal Multisystem Atrophy (MSA) with ENT-01","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Squalamine Phosphate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enterin \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Squalamine phosphate

    Menu

    Squalamine phosphate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enterin

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Enterin

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Squalamine phosphate

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enterin Announces FDA Acceptance of An Investigator Sponsored IND To Treat a Patient with Prodromal Multisyste...

                            Details : Enterin’s oral lead compound, ENT-01 which prevents alpha synuclein from accumulating and aggregating within the enteric nervous system, receives FDA acceptance of an investigator sponsored IND application to treat a patient with prodromal multisystem ...

                            Brand Name : ENT-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Squalamine phosphate

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth